uniQure NV (QURE) Shares Down 1.6%
uniQure NV (NASDAQ:QURE) traded down 1.6% during trading on Friday . The company traded as low as $6.96 and last traded at $7.16, with a volume of 125,485 shares. The stock had previously closed at $7.28.
A number of equities research analysts have recently commented on the stock. Leerink Swann reiterated a “buy” rating on shares of uniQure NV in a report on Sunday, June 12th. Cowen and Company reiterated a “buy” rating on shares of uniQure NV in a report on Thursday, June 2nd. Chardan Capital set a $35.00 price target on shares of uniQure NV and gave the stock a “buy” rating in a report on Thursday. Jefferies Group set a $28.00 price target on shares of uniQure NV and gave the stock a “buy” rating in a report on Thursday. Finally, Oppenheimer Holdings Inc. reiterated a “buy” rating and set a $23.00 price target (down from $50.00) on shares of uniQure NV in a report on Tuesday, April 5th. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $30.00.
The stock’s 50 day moving average price is $7.85 and its 200-day moving average price is $12.35. The company’s market capitalization is $180.43 million.
uniQure NV (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.82) by $0.10. Analysts anticipate that uniQure NV will post ($3.51) EPS for the current year.
Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.